AXOGEN INC (AXGN) Stock Price & Overview

NASDAQ:AXGN • US05463X1063

Current stock price

34.06 USD
+0.48 (+1.43%)
Last:

The current stock price of AXGN is 34.06 USD. Today AXGN is up by 1.43%. In the past month the price increased by 14.92%. In the past year, price increased by 107.03%.

AXGN Key Statistics

52-Week Range9.215 - 35.9999
Current AXGN stock price positioned within its 52-week range.
1-Month Range27.54 - 34.22
Current AXGN stock price positioned within its 1-month range.
Market Cap
1.768B
P/E
117.45
Fwd P/E
65.57
EPS (TTM)
0.29
Dividend Yield
N/A

AXGN Stock Performance

Today
+1.43%
1 Week
+0.90%
1 Month
+14.92%
3 Months
+8.32%
Longer-term
6 Months +87.81%
1 Year +107.03%
2 Years +423.87%
3 Years +272.28%
5 Years +79.38%
10 Years +476.98%

AXGN Stock Chart

AXOGEN INC / AXGN Daily stock chart

AXGN Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to AXGN. When comparing the yearly performance of all stocks, AXGN is one of the better performing stocks in the market, outperforming 90.91% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

AXGN Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to AXGN. The financial health of AXGN is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

AXGN Earnings

On February 24, 2026 AXGN reported an EPS of 0.07 and a revenue of 59.90M. The company missed EPS expectations (-29.35% surprise) and missed revenue expectations (-0.64% surprise).

Next Earnings DateMay 6, 2026
Last Earnings DateFeb 24, 2026
PeriodQ4 / 2025
EPS Reported$0.07
Revenue Reported59.904M
EPS Surprise -29.35%
Revenue Surprise -0.64%

AXGN Forecast & Estimates

17 analysts have analysed AXGN and the average price target is 41.62 USD. This implies a price increase of 22.18% is expected in the next year compared to the current price of 34.06.

For the next year, analysts expect an EPS growth of 79.12% and a revenue growth 18.41% for AXGN


Analysts
Analysts83.53
Price Target41.62 (22.2%)
EPS Next Y79.12%
Revenue Next Year18.41%

AXGN Groups

Sector & Classification

AXGN Financial Highlights

Over the last trailing twelve months AXGN reported a non-GAAP Earnings per Share(EPS) of 0.29. The EPS increased by 123.08% compared to the year before.


Income Statements
Revenue(TTM)225.21M
Net Income(TTM)-15.70M
Industry RankSector Rank
PM (TTM) N/A
ROA -7.08%
ROE -12.19%
Debt/Equity 0.38
Chartmill High Growth Momentum
EPS Q2Q%0%
Sales Q2Q%21.25%
EPS 1Y (TTM)123.08%
Revenue 1Y (TTM)20.21%

AXGN Ownership

Ownership
Inst Owners82.91%
Shares51.90M
Float49.76M
Ins Owners1.31%
Short Float %6.15%
Short Ratio3.05

About AXGN

Company Profile

AXGN logo image Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. The company is headquartered in Alachua, Florida and currently employs 622 full-time employees. The company offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating.

Company Info

IPO: 1986-12-17

AXOGEN INC

13631 Progress Blvd., Suite 400

Alachua FLORIDA 32615 US

CEO: Karen Zaderej

Employees: 622

AXGN Company Website

AXGN Investor Relations

Phone: 13864626817

AXOGEN INC / AXGN FAQ

What does AXGN do?

Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. The company is headquartered in Alachua, Florida and currently employs 622 full-time employees. The company offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating.


What is the current price of AXGN stock?

The current stock price of AXGN is 34.06 USD. The price increased by 1.43% in the last trading session.


What is the dividend status of AXOGEN INC?

AXGN does not pay a dividend.


What is the ChartMill technical and fundamental rating of AXGN stock?

AXGN has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


What is the GICS sector and industry of AXGN stock?

AXOGEN INC (AXGN) operates in the Health Care sector and the Health Care Equipment & Supplies industry.


Would investing in AXOGEN INC be a good decision?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on AXGN.


What is the ownership structure of AXOGEN INC (AXGN)?

You can find the ownership structure of AXOGEN INC (AXGN) on the Ownership tab.